Pharmaceutical industry – Page 44
-
BusinessPharma firms rush to escape US tax shackles
AbbVie–Shire and Mylan–Abbott mergers both allow US firms to escape to lower-tax European countries
-
Business
China struggles to speed up drug reviews
Regulator considers outsourcing reviews, and creates a fast-track scheme for priority generics
-
Business
First of a new breed of anticancer antibodies approved in Japan
Ono claims Opdivo is the first anti-PD1 treatment in the world
-
BusinessEMA wrangles restrain trial data progress
Attempts to balance industry and research interests on transparency draw suggestions of improper collusion
-
Business
Genentech to buy breast cancer specialist Seragon
$1.7bn deal for hormone receptor-destroying drug pipeline
-
Business
Inhaled insulin approved in US
European committee recommends approval for generic long-acting insulin
-
Business
Affymax folds after drug withdrawal
Unexplained allergic reactions to anaemia drug prompt firm to dissolve
-
Business
Biotech bounced back in 2013, says report
R&D investment increasing, but industry needs to use its cash more wisely
-
Business
Shire fends off AbbVie takeover bid
Board says deal undervalues the company and its growth potential
-
Business
Medtronic to buy Covidien for $43bn
Tax inversion deal continues consolidation theme among medical device makers
-
Business
Novo Nordisk to create 6000 jobs by 2022
Half of the new Danish employees will be in R&D roles
-
BusinessPharma vies to unleash immune system power on cancer
Immuno-oncological drugs look set to earn billions and significantly lengthen patients’ lives
-
Business
Merck & Co bolsters hepatitis C pipeline with Idenix acquisition
Early-stage drugs complement Merck’s own developmental portfolio
-
Business
Drug giants settle mismarketing lawsuits
Pfizer and GSK settle claims over promoting drugs for unapproved uses in the US
-
Business
Generics giants jostle over pain drug
Mylan and Actavis contest Teva’s generic celecoxib exclusivity
-
Business
Drug companies rapped for anticompetitive behaviour
Italian authorities demand €1.2 billion in damages from Roche, Novartis and Pfizer
-
OpinionMessy megamergers
Big company buyouts are more about immediate gains and rarely consider the impact on research, says Derek Lowe
-
BusinessChinese-made DNA sequencer aims to challenge foreign dominance
Domestic instrument pitching for a slice of the world’s fastest growing genome sequencing market
-
Business
Boehringer to settle blood thinner drug suits for $650m
Company confident in drug safety but says court cases are too risky
-
Business
Time called on Pfizer–AstraZeneca deal
Pfizer could make a fresh approach after six months under City takeover rules